{"id":755,"date":"2026-09-01T16:45:45","date_gmt":"2026-09-01T16:45:45","guid":{"rendered":"https:\/\/nhdbio.com\/resources\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"modified":"2026-09-01T16:45:45","modified_gmt":"2026-09-01T16:45:45","slug":"bremelanotide-reconnect-phase-3-trials-and-fda-label","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/pt-br\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","title":{"rendered":"Ensaios de Bremelanotida RECONNECT: Endpoints, Seguran\u00e7a e Escopo FDA"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">A bremelanotida tem um registro real de medicamento acabado aprovado pelo FDA, mas seu escopo \u00e9 estreito. Os ensaios RECONNECT estudaram mulheres na pr\u00e9-menopausa com HSDD adquirido e generalizado \u2013 n\u00e3o homens, melhoria de desempenho ou um material de pesquisa gen\u00e9rico do PT-141.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Evid\u00eancias em resumo<\/h2><ul class=\"wp-block-list\"><li>Os ensaios 3 de duas fases randomizaram mulheres 1,267; 1,202 estavam na popula\u00e7\u00e3o de efic\u00e1cia.<\/li><li>As mudan\u00e7as entre os grupos favoreceram a bremelanotida nos desfechos de desejo e sofrimento, mas uma medida post-hoc de evento satisfat\u00f3rio n\u00e3o diferiu significativamente.<\/li><li>N\u00e1useas, rubor e dor de cabe\u00e7a ocorreram pelo menos em 10% e foram mais comuns do que com placebo.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1672\" height=\"941\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp\" alt=\"Visualiza\u00e7\u00e3o de evid\u00eancias regulat\u00f3rias e de dois ensaios para bremelanotida\" class=\"wp-image-739\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp 1672w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence-300x169.webp 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence-1024x576.webp 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence-768x432.webp 768w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence-1536x864.webp 1536w\" sizes=\"auto, (max-width: 1672px) 100vw, 1672px\" \/><figcaption class=\"wp-element-caption\">Ilustra\u00e7\u00e3o original da pesquisa editorial. N\u00e3o se trata de figura de estudo, imagem de paciente, fotografia de produto, resultado de ensaio fornecido ou representa\u00e7\u00e3o de lote de cat\u00e1logo.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">Registro de estudo<\/h2><p class=\"wp-block-paragraph\">Os desfechos coprim\u00e1rios foram a mudan\u00e7a na pontua\u00e7\u00e3o do dom\u00ednio do desejo FSFI e um item de sofrimento do FSDS-DAO. As diferen\u00e7as de desejo espec\u00edficas do estudo foram 0.30 e 0.42; as diferen\u00e7as de sofrimento foram \u22120.37 e \u22120.29. A signific\u00e2ncia estat\u00edstica n\u00e3o descreve por si s\u00f3 o tamanho ou a relev\u00e2ncia do benef\u00edcio para cada indiv\u00edduo.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Projeto<\/strong><span>Dois ensaios id\u00eanticos de fase 3, randomizados, duplo-cegos e controlados por placebo<\/span><\/div><div class=\"pim-evidence-row\"><strong>Randomizado<\/strong><span>1,267 mulheres na pr\u00e9-menopausa<\/span><\/div><div class=\"pim-evidence-row\"><strong>Diferen\u00e7a de desejo integrada<\/strong><span>0.35 versus placebo; P&lt;0.001<\/span><\/div><div class=\"pim-evidence-row\"><strong>Diferen\u00e7a de ang\u00fastia integrada<\/strong><span>\u22120.33 versus placebo; P&lt;0.001<\/span><\/div><div class=\"pim-evidence-row\"><strong>Limite do r\u00f3tulo<\/strong><span>N\u00e3o indicado para mulheres, homens, crian\u00e7as na p\u00f3s-menopausa ou para melhoria de desempenho<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Resultados no contexto<\/h2><p class=\"wp-block-paragraph\">O artigo n\u00e3o relata nenhuma diferen\u00e7a significativa entre grupos na porcentagem de eventos sexuais satisfat\u00f3rios em uma an\u00e1lise post-hoc. Preservar essa constata\u00e7\u00e3o nula mant\u00e9m o registro mais informativo do que um resumo apenas de benef\u00edcios.<\/p><p class=\"wp-block-paragraph\">A rotulagem atual do DailyMed identifica Vyleesi como inje\u00e7\u00e3o de bremelanotida sob NDA 210557 e lista aumento transit\u00f3rio da press\u00e3o arterial, diminui\u00e7\u00e3o da frequ\u00eancia card\u00edaca, n\u00e1usea e hiperpigmenta\u00e7\u00e3o focal entre informa\u00e7\u00f5es de seguran\u00e7a importantes. Este r\u00f3tulo pertence \u00e0 formula\u00e7\u00e3o aprovada e n\u00e3o a um item de cat\u00e1logo de pesquisa.<\/p><h2 class=\"wp-block-heading\">O que a evid\u00eancia n\u00e3o pode estabelecer<\/h2><p class=\"wp-block-paragraph\">A popula\u00e7\u00e3o de evid\u00eancias e a indica\u00e7\u00e3o s\u00e3o espec\u00edficas; alega\u00e7\u00f5es mais amplas de desempenho sexual n\u00e3o s\u00e3o apoiadas.<\/p><p class=\"wp-block-paragraph\">Os ensaios principais foram financiados pela ind\u00fastria.<\/p><p class=\"wp-block-paragraph\">Uma por\u00e7\u00e3o activa aprovada n\u00e3o transforma um material de origem independente num medicamento aprovado.<\/p>","protected":false},"excerpt":{"rendered":"<p>A bremelanotida tem um registro real de medicamento acabado aprovado pelo FDA, mas seu escopo \u00e9 estreito. Os ensaios RECONNECT estudaram mulheres na pr\u00e9-menopausa com HSDD adquirido e generalizado \u2013 n\u00e3o homens, melhoria de desempenho ou um material de pesquisa gen\u00e9rico do PT-141.<\/p>","protected":false},"author":1,"featured_media":739,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"358","pim_article_type":"Published evidence review","pim_evidence_level":"Two randomized phase 3 trials plus current FDA-approved prescribing information","pim_reviewer":"Site evidence editorial team","pim_reviewed_date":"2026-09-02","pim_editorial_note":"Source-checked on 2026-09-02. Null results, study size, model\/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"Primary\/regulatory sources, factual claims, numerical results, limitations and product-evidence boundary checked for batch 3.","pim_creation_method":"The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA\/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.","pim_sources":"[{\"title\":\"RECONNECT bremelanotide phase 3 trials\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31599840\/\",\"note\":\"Primary phase 3 publication; PMID 31599840.\"},{\"title\":\"DailyMed Vyleesi prescribing information\",\"url\":\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf\",\"note\":\"Current FDA-approved finished-drug label.\"},{\"title\":\"PubChem Bremelanotide record\",\"url\":\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Bremelanotide\",\"note\":\"Free-base peptide identity; CID 9941379.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope<\/title>\n<meta name=\"description\" content=\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/pt-br\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\" \/>\n<meta property=\"og:description\" content=\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/pt-br\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T16:45:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\",\"name\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"description\":\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"width\":1672,\"height\":941,\"caption\":\"AI-generated illustration: Regulatory and two-trial evidence visualization for bremelanotide\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/pt-br\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ensaios de Bremelanotida RECONNECT: Endpoints, Seguran\u00e7a e Escopo FDA","description":"A bremelanotida tem um registro real de medicamento acabado aprovado pelo FDA, mas seu escopo \u00e9 estreito. Os ensaios RECONNECT estudaram mulheres na pr\u00e9-menopausa com doen\u00e7as adquiridas, gen\u00e9ricas\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/pt-br\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","og_locale":"pt_BR","og_type":"article","og_title":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope","og_description":"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026","og_url":"https:\/\/nhdbio.com\/pt-br\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","og_site_name":"NHD","article_published_time":"2026-09-01T16:45:45+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope","datePublished":"2026-09-01T16:45:45+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","articleSection":["Published Study Reviews"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","url":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","name":"Ensaios de Bremelanotida RECONNECT: Endpoints, Seguran\u00e7a e Escopo FDA","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","datePublished":"2026-09-01T16:45:45+00:00","description":"A bremelanotida tem um registro real de medicamento acabado aprovado pelo FDA, mas seu escopo \u00e9 estreito. Os ensaios RECONNECT estudaram mulheres na pr\u00e9-menopausa com doen\u00e7as adquiridas, gen\u00e9ricas\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","width":1672,"height":941,"caption":"AI-generated illustration: Regulatory and two-trial evidence visualization for bremelanotide"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mat\u00e9rias-primas pept\u00eddicas e s\u00edntese personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipe T\u00e9cnica NHD","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"A equipe t\u00e9cnica NHD mant\u00e9m documenta\u00e7\u00e3o de cat\u00e1logo de uso em pesquisa e resumos de evid\u00eancias. Os artigos revisados \u200b\u200bvinculam-se a artigos revisados \u200b\u200bpor pares, registros de ensaios e registros regulat\u00f3rios, ret\u00eam resultados nulos e limita\u00e7\u00f5es de estudos e distinguem interven\u00e7\u00f5es publicadas de materiais de cat\u00e1logo. O desenho assistido por AI pode ser usado para estrutura; os links de origem e os limites das evid\u00eancias permanecem vis\u00edveis. Este trabalho n\u00e3o \u00e9 uma revis\u00e3o independente por pares ou aconselhamento m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/pt-br\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/comments?post=755"}],"version-history":[{"count":0,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/posts\/755\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media\/739"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/media?parent=755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/categories?post=755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/pt-br\/wp-json\/wp\/v2\/tags?post=755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}